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Endoleak as a predictor of outcome after
endovascular aneurysm repair: AneuRx
multicenter clinical trial
Christopher K. Zarins, MD,a Rodney A. White, MD,b Kim J. Hodgson, MD,c
Donald Schwarten, MD,d and Thomas J. Fogarty, MD,a for the AneuRx
Clinical Investigators, Stanford and Torrance, Calif, Springfield, Ill, and
Indianapolis, Ind
Objective: The purpose of this study was to determine whether evidence of blood flow in
the aneurysm sac (endoleak) is a meaningful predictor of clinical outcome after success-
ful endovascular aneurysm repair.
Methods: We reviewed all patients in Phase II of the AneuRx Multicenter Clinical Trial
with successful stent graft implantation and predischarge contrast computed tomo-
graphic (CT) imaging. The clinical outcome of patients with evidence of endoleak was
compared with the outcome of patients without evidence of endoleak. The CT endoleak
status before hospital discharge at 6, 12, and 24 months was determined by each clini-
cal center as well as by an independent core laboratory. Endoleak status at 1 month was
assessed with duplex scanning examination or CT at each center without confirmation
by the core laboratory. 
Results: Centers reported endoleaks in 152 (38%) of 398 patients on predischarge CT,
whereas the core laboratory reported endoleaks in 50% of these patients (P < .001). The
center-reported endoleak rate decreased to 13% at 1 month. Follow-up extended to 2
years (mean, 10 ± 4 months). One patient had aneurysm rupture and underwent suc-
cessful open repair at 14 months. This patient had a Type I endoleak at discharge but
no endoleak at 1 month or at subsequent follow-up times. There were no differences
between patients with and patients without endoleak at discharge in the following out-
come measures: patient survival, aneurysm rupture, surgical conversion, the need for an
additional procedure for endoleak or graft patency, aneurysm enlargement more than 5
mm, the appearance of a new endoleak, or stent graft migration. Despite a higher
endoleak rate identified by the core laboratory, neither the endoleak rate reported by the
core laboratory nor the endoleak rate reported by the center at discharge was signifi-
cantly related to subsequent outcome measures. Patients with endoleak at 1 month were
more likely to undergo an additional procedure for endoleak than patients without
endoleaks. Patients with Type I endoleaks at discharge and patients with endoleak at 1
month were more likely to experience aneurysm enlargement at 1 year. However, there
was no difference in patient survival, aneurysm rupture rate, or primary or secondary
success rate between patients with or without endoleak. Actuarial survival of all patients
undergoing endovascular aneurysm repair was 96% at 1 year and was independent of
endoleak status. Primary outcome success was 92% at 12 months and 88% at 18 months.
Secondary outcome success was 96% at 12 months and 94% at 18 months.
Conclusions: The presence or absence of endoleak on CT scan before hospital discharge
does not appear to predict patient survival or aneurysm rupture rate after endovascular
aneurysm repair using the AneuRx stent graft. Although the identification of blood flow
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Complete aneurysm exclusion with no endoleak is
considered a primary end point of endovascular
aneurysm repair. Successful aneurysm exclusion has
been achieved in 50% to 90% of cases1-8 with the use
of a variety of endovascular grafts. Continued blood
flow in the aneurysm sac (endoleak) has been reported
in 15% to 52% of patients after endovascular repair9-14
and is regarded as evidence that the risk of aneurysm
rupture has not been eliminated. Conversely, absence
of blood flow in the aneurysm sac is viewed as evidence
that the patient is no longer at risk for aneurysm rup-
ture. Although aneurysm ruptures have been reported
in patients with endoleak after endovascular aneurysm
repair,5,10,13,15-17 ruptures have also been reported in
patients with no endoleak and decreasing aneurysm
size.18,19 Thus, the risk of rupture in patients with evi-
dence of perigraft flow is unknown. The purpose of
this investigation was to determine whether evidence
of blood flow in the aneurysm sac after successful
endovascular aneurysm repair is a meaningful predic-
tor of clinical outcome. 
METHODS
All patients treated during Phase II of the multi-
center clinical trial of endovascular aneurysm repair
with the Medtronic AneuRx stent graft system
(Santa Rosa, Calif) were reviewed. Details of the
study design, patient eligibility, and inclusion and
exclusion criteria have been previously reported.4
Thirteen clinical sites participated in this study (see
addendum), and all patients were entered into the
trial between April 1997 and October 1998. Each
study site received Institutional Review Board
approval, and all patients gave informed consent.
Each patient met the inclusion criteria of an
abdominal aortic aneurysm with an infrarenal neck
length of at least 10 mm and a neck diameter between
18 and 26 mm with a maximum distal iliac diameter
of 15 mm. Patients were treated with the modular,
bifurcated AneuRx stent graft in the operating room
or endovascular radiology suite with completion
angiographic imaging. Before hospital discharge, con-
trast computed tomographic (CT) angiography was
performed on all patients to document the position
and patency of the stent graft and to evaluate the size
of the aneurysm and the presence or absence of peri-
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graft flow in the aneurysm sac (endoleak). One
month after endovascular repair, patients underwent
imaging of the aneurysm and stent graft with the use
of either duplex ultrasound scanning or contrast CT
or both, as determined by each center. Patients were
thereafter imaged with contrast CT at 6 months, 12
months, and 24 months. Abdominal radiographs
were taken before discharge at 1 month, 6 months,
12 months, and annually thereafter to evaluate device
integrity and migration. Additional imaging was per-
formed as clinically indicated.
Full data sets and selected cross-sectional images of
noncontrast- and contrast-infused spiral CT scans
were evaluated by the radiologists and investigators at
each study site (centers) before hospital discharges and
at each subsequent follow-up interval and reported to
the AneuRx clinical database. Selected cross-sectional
images of the predischarge CT, 6-month CT, and 12-
month CT, along with abdominal radiographs, were
sent for blinded reading to an independent radiology
group (core laboratory), which had no involvement
with any of the clinical investigation sites.
Aneurysm and neck diameter and length, stent
graft patency and configuration, evidence of perigraft
contrast in the aorta or aneurysm sac (endoleak), and
position of the stent graft in relation to the native
aorta and L1 vertebral body were recorded. Endoleaks
were classified by the core laboratory as to location:
proximal, distal, or junctional attachment site (Type
I); branch vessel flow (Type II); and undetermined.
An increase or decrease in maximum aneurysm diam-
eter by more than 5 mm compared with predischarge
CT imaging at any time during the follow-up or
between any two consecutive follow-up intervals was
considered to be a significant diameter change.
Patients were grouped according to whether an
endoleak was present, and analysis was performed
according to endoleak status as defined by (a) investi-
gational site (centers) report of endoleak based on pre-
discharge CT, (b) core laboratory report of endoleak
based on review of same predischarge CT scans as in
(a), and (c) investigational site (centers) report of
endoleak at 1 month determined by CT or duplex
scan. Outcome related to endoleak type was based on
core laboratory classification of Type I and Type II
endoleaks. The following outcome measures were
in the aneurysm sac after endovascular repair is a meaningful finding and may at times
indicate inadequate stent graft fixation, the usefulness of endoleak as a primary indica-
tor of procedural success or failure is unclear. Therefore, all patients who have under-
gone endovascular aneurysm repair should be carefully followed up regardless of
endoleak status. (J Vasc Surg 2000;32:90-107.)
used: death, aneurysm rupture, conversion to open
surgical repair, stent graft patency, additional proce-
dure for endoleak or nonpatency, aneurysm enlarge-
ment, new endoleak, and stent graft migration.
Results are reported as the mean and SD.
Statistical differences between groups were evaluated
with the 2-tailed Student t test, Wilcoxon rank sum
test, χ2 analysis, Fischer exact test, and McNemar
test, as appropriate. Differences are reported as sig-
nificant if the P value was equal to or less than .05.
RESULTS
Among the 425 patients entered into Phase II, the
AneuRx bifurcation stent graft was successfully
deployed in 414 (97%). In three patients, no treat-
ment attempt was made. In eight patients (2%) the
iliac arteries were too small or tortuous to introduce
the device. Six patients died in the hospital (hospital
mortality rate, 1%), and five underwent open surgical
repair (surgical conversion rate, 1%). Postimplantation
CT imaging was not obtained or unavailable for
review in nine patients. Thus, there were 398 Phase II
patients with successful implantation and predischarge 
CT imaging available for analysis.
Endoleak evaluation
Predischarge CT scans were performed within 2
days of stent graft insertion in 89% of patients, with-
in 4 days in 95% of patients, and within 1 week in
98% of patients. Investigational sites (centers)
reported endoleaks in 152 (38%) of 398 patients
and no endoleaks in 246 (62%) of 398 patients on
the basis of noncontrast- and contrast-infused CT
scans before hospital discharge. The core laborato-
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Fig 1. Kaplan-Meier survival curves for patients with and without endoleak after successful endovas-
cular aneurysm repair. A, Endoleak status before hospital discharge. 
A
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ry reported endoleaks in 175 (50%) of 350 patients
and no endoleaks in 175 (50%) of 350 patients on
the basis of its review of selected images of the same
predischarge contrast CT. The core laboratory
endoleak rate was significantly higher (P < .001)
than that reported by the centers. 
Endoleak status at 1 month was documented
with the use of either duplex ultrasound scanning or
contrast CT as determined by each center. CT scans
were not required by the study protocol, and no
evaluation by the core laboratory was performed.
One-month evaluation was performed with duplex
ultrasound scanning in 254 patients (67%), contrast
CT scans in 124 patients (33%), and magnetic reso-
nance angiography in one patient. Endoleak was
documented in 51 (13%) of 379 patients, and no
endoleak was present in 328 (87%) of 379 patients.
Mean time to last follow-up was 10 months with a
range of 1 to 25 months. There were 242 patients
(61%) who had 1-year follow-up data, and seven
patients had 2-year follow-up data.
Patient characteristics
Baseline patient characteristics and risk factors
were recorded before endovascular treatment.
Patients with or without endoleak on predischarge
CT as defined by the centers are shown in Table I.
Patients with endoleak were slightly older, had a
higher rate of treatment of coronary artery disease,
had a higher rate of alcoholism, and had a more fre-
quent history of prior abdominal or pelvic radiation.
There were no differences in other baseline (preop-
erative) risk factors or patient characteristics.
Multivariate analysis to control for these differences
Fig 1 Cont’d. B, Endoleak status at 1 month.
B
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in baseline characteristics did not alter the results of
group comparisons.
When patients were grouped according to
endoleak status as defined by the core laboratory
reading of the predischarge CT, there were no dif-
ferences between patients with endoleak (n = 175)
and those without endoleak (n = 175), except for a
higher rate of alcoholism in the endoleak group (P =
.048). Multivariate analysis to control for this differ-
ence in baseline characteristics did not alter the
results of group comparisons.
When patients were grouped according to
endoleak status at 1 month as determined by the cen-
ters, there were no significant differences in baseline
patient characteristics between patients with and those
without endoleak, with the exception of increased
smoking history in patients without endoleak (85%)
than in those with endoleak (73%, P = .03). Statistical
adjustment for this baseline difference did not alter
the outcome analysis of the 1-month patient analysis. 
Preoperative aneurysm morphology
There were no differences in preoperative
aneurysm morphology between patients with
endoleak and without endoleak as defined by either
the centers or core laboratory (Table II). Morphologic
features evaluated included aneurysm diameter, neck
diameter, neck length and aneurysm length, and the
degree of calcification and thrombus. Also evaluated
was whether the aneurysm was localized to the aorta
alone (Class A and B) or involved the iliac arteries
(Class C, D, and E) (Table II).
Endoleaks after endovascular aneurysm repair
The endoleak rate before hospital discharge was
38% as reported by the centers and 50% as reported by
the core laboratory (P < .001). The endoleak rate at 1
month was determined by the centers to be 13%. The
endoleak rate reported by the centers was 16% at 6
months and 13% at 1 year, compared with an endoleak
rate of 27% at 6 months and 20% at 1 year reported by
the core laboratory (P < .001) (Table III). Although
there was a consistently higher endoleak rate reported
by the core laboratory, there was no difference in the
rate of detection of new endoleaks (6%), stent graft
migration (2%), or aneurysm enlargement (6%)
between the center and core laboratory readings. 
Endoleaks were classified by the core laboratory
as Type I (attachment site) in 54 patients (31%),
Type II (branch flow) in 70 patients (40%), and
undetermined in 51 patients (29%). Among the 54
Type I endoleaks, there were 16 proximal (30%), 3
distal (6%), 22 junctional (40%), and 13 extender
cuff (24%) endoleaks. Among the 70 Type II
Fig 2. Aneurysm rupture 14 months after endovascular aneurysm repair. A, CT of 6.8-cm aneurysm
before endovascular repair. B, Endoleak is demonstrated on CT scan 24 hours after endovascular
repair. C, CT scan at 1 and 6 months reveals no endoleak and no change in aneurysm size. D, CT scan
at 14 months reveals rupture and aneurysm enlargement to 7.5 cm.
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endoleaks, 67 (96%) were primarily related to lum-
bar arteries, whereas three (4%) were primarily relat-
ed to the inferior mesenteric artery.
Deaths 
Twenty patients have died during the follow-up
period. No patient died of aneurysm rupture. There
was no difference in the mortality rate for patients with
endoleak (5%) on predischarge CT compared with
patients without endoleak (5%). There was no differ-
ence in mortality rate between center-defined and core
laboratory–defined endoleak. There was no difference
in the mortality rate between patients with or without
endoleak at 1 month (Table IV). Ten patients have died
of cardiac causes, 2 of strokes, 1 of pneumonia, 5 of
cancer, and 2 of gastrointestinal disorders. Life
table/Kaplan-Meier analysis reveals no difference in
survival of patients, with or without predischarge
endoleak as defined by the centers or core laboratory
(Fig 1). There was no difference in life table survival
between patients with or without endoleak at 1 month. 
Aneurysm rupture 
One patient had aneurysm rupture 14 months
after endovascular aneurysm repair. This man was aged
80 years and had severe coronary artery disease and a
6.8-cm abdominal aortic aneurysm before endovascu-
lar repair. One day after successful placement of the
stent graft, contrast CT revealed a minor endoleak at
the iliac junction, by both center and core laboratory
reading. One month later the center reported no
endoleak, and aneurysm size was unchanged. The core
laboratory reviewed this CT scan and confirmed the
findings. The CT scan performed at 6 months revealed
no endoleak and no change in aneurysm size. At the
1-year follow-up, the patient refused CT scanning.
Duplex ultrasound scanning revealed no endoleak.
Two months later the patient experienced back pain,
and a CT scan demonstrated rupture of the aneurysm,
which now measured 7.5 cm with endoleak and con-
trast extravasation (Fig 2). The patient underwent
emergent operation with successful open repair of his
aneurysm. At operation insecure proximal fixation of
the stent graft in a short angulated neck was identified
as the cause of rupture. The iliac junction, the source
of the early endoleak, was intact.
Open surgical repair
Two patients (0.5%) underwent open surgical
repair (surgical conversion) during the follow-up
Table I. Preoperative patient characteristics*
Endoleak No endoleak
(N = 152 [38%]) (N = 246 [62%]) P value
Age (y) 75 ± 7 73 ± 9 < .05
Sex (M:F) 89%:11% 91%:9% ns
ASA class 
1 0% 2% ns
2 9% 11% ns
3 62% 67% ns
4 30% 20% ns
Aneurysm diameter (cm) 5.6 ± 1.0 5.5 ± 0.9 ns
Family history AAA 10% 11% ns
Smoking 83% 84% ns
Hypertension 66% 63% ns
COPD 24% 24% ns
Diabetes 13% 12% ns
Prior MI/angina 56% 55% ns
Symptomatic arrhythmia 13% 12% ns
CPTA/CABG 52% 42% < .05
Cerebrovascular disease 14% 12% ns
PVOD 18% 19% ns
Obesity 14% 18% ns
Chronic renal failure 3% 2% ns
Alcohol 6% 2% < .05
Cancer 28% 25% ns
Previous surgery in abdomen/pelvis 27% 25% ns
Previous radiation in abdomen/pelvis 6% 2% < .05
*Endoleak status defined by predischarge CT (centers).
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiologists risk classification; CABG, coronary artery bypass graft-
ing; COPD, chronic obstructive pulmonary disease; CPTA, coronary percutaneous transluminal angioplasty; MI, myocardial infarction;
ns, not significant; PVOD, pulmonary vascular obstructive disease.
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period. One was the patient with rupture, described
above. A second patient had endoleak at discharge,
at 1 month, and at 6 months because of a proximal
Type I endoleak with no change in aneurysm size.
The patient declined a recommendation to place a
proximal extender cuff and chose to undergo elec-
tive open surgical repair. 
Additional procedures 
Twenty-two patients (6%) underwent secondary
treatments during the follow-up period for endoleak
or nonpatency. Of these, 15 were for endoleak, and
seven were for graft limb occlusion.
Endoleak. Fifteen patients (4%) with endoleak
were treated with a secondary endovascular proce-
dure from 2 weeks to 16 months after the initial
stent graft repair. Most were treated more than 6
months after stent graft placement. Of these, nine
had endoleak at hospital discharge, and six had no
endoleak. At 1 month, eight continued to have
endoleak, and seven had no endoleak. Nine patients
were treated for persisting endoleaks at 2 weeks to
13 months (mean, 6 months); five patients were
treated with proximal extender cuffs, three with dis-
tal extender cuffs, and one with both proximal and
distal extenders. The endoleak was successfully
sealed in three patients and persists in six patients.
Six patients had no endoleak at hospital dis-
charge, and five of the six had no endoleak at 1
month. New endoleaks were identified at 1 month
in one patient and between 8 and 16 months (mean,
12 months) in five patients. All six were successfully
Fig 3. Kaplan-Meier primary outcome estimates (no death, no aneurysm rupture, no conversion to
open repair, and no additional procedure for endoleak or nonpatency of the stent graft) for patients
with and those without endoleaks at (A) hospital discharge.
A
treated with elimination of the leak. Three patients
had proximal extender cuffs, two had distal extender
cuffs, and one had both proximal and distal extenders.
Nonpatency. Seven patients (2%) had occlusion
or obstruction of one limb of the stent graft 1 week
to 6 months after stent graft repair. Of these
patients, three had endoleak, and four had no
endoleak at the time of hospital discharge. At 1
month, none had evidence of endoleak. Five patients
were treated within 1 month, one was treated at 6
weeks, and one was treated at 6 months to restore
blood flow. Graft patency was restored in four
patients, three with thrombectomy and femoral
artery revision and one with thrombolysis, angio-
plasty, and stent placement. In two patients, flow
was restored with femoral-femoral bypass grafting,
and in one patient flow was restored with an axil-
lopopliteal bypass graft. Thus, primary graft patency
was 98%, and secondary graft patency was 99%. Flow
was restored to the lower extremities in all patients.
There was no difference in the rate of additional
procedures performed on the basis of endoleak sta-
tus as determined by either the centers or core labo-
ratory before hospital discharge (Table IV). Patients
with endoleak at 1 month were more likely to
undergo an additional procedure during the follow-
up period (16%) compared with patients with no
endoleak at 1 month (4%, P < .01). 
New endoleaks
A new endoleak was defined as contrast enhance-
ment of the aneurysm sac on CT scan in a patient
with no evidence of endoleak on the previous study. A
new endoleak during the course of the study was doc-
umented by the centers in 9% of patients and by the
core laboratory in 6% of patients. There was no dif-
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Fig 3 Cont’d. Primary outcome measure at (B) 1 month.
B
ference in the appearance rate of new endoleaks
between patients with and without endoleak at hospi-
tal discharge as determined by the centers or the core
laboratory. There was no difference in new endoleak
between patients with and without endoleak at 1
month (Table IV). Among the 32 patients with new
onset endoleak identified by the centers, six (19%)
had an additional procedure that successfully treated
the endoleak; three of these new endoleaks were relat-
ed to stent graft migration described below.
Aneurysm enlargement 
Aneurysm enlargement was defined as an
increase in maximum aneurysm diameter by more
than 0.5 cm from predischarge imaging at any time
during the follow-up period or between any two
consecutive follow-up intervals. Aneurysm diameter
on the predischarge CT was used as the baseline for
comparison of aneurysm diameter changes during
the follow-up period. This baseline was selected
because the predischarge CT was performed, on
average, 2 days after endovascular repair, whereas
there was considerable variability in the time interval
(sometimes several month delays) between the pre-
operative CT and placement of the stent graft. In
addition, the preprocedure CT was often done at an
outside referring hospital, which was different from
the study center with variability in technique.
Six months after endovascular repair, aneurysm
diameter had not changed in 88% to 89% of patients
(Table V). In 2% to 4% of patients, aneurysm diame-
ter increased more than 5 mm, and in 7% to 10% of
patients aneurysm diameter decreased more than 5
mm. There was no statistical difference in diameter
changes between patients with and without endoleak
and no difference between patients with center-
defined and core laboratory–defined endoleaks.
After 12 months, aneurysm diameter was
increased by more than 5 mm in 1% to 8% of
patients, was decreased by more than 5 mm in 14%
to 25% of patients, and was unchanged in approxi-
mately 75% of patients. There were no significant
differences in aneurysm diameter changes between
patients with and those without endoleak at hospital
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Table III. Endoleaks after endovascular aneurysm repair: posttreatment CT imaging*
Centers (N = 398) Core laboratory (N = 350) P value
Endoleak at
Hospital discharge 152/398 38% 175/350 50% < .001
6 mo 57/359 16% 71/264 27% < .001
12 mo 32/252 13% 30/151 20% < .001
New endoleak (at any time) 16/288 6% 16/283 6% ns
Migration (at any time) 8/375 2% 7/325 2% ns
Aneurysm enlargement > 5 mm (at any time) 22/398 6% 20/350 6% ns
Center data verified by external auditors and entered into central database.
Core laboratory independent blinded review.
*Comparison of center vs core laboratory reading.
ns, Not significant.
Table II. Aneurysm morphology: preoperative CT imaging
Centers (n = 398) Core laboratory (n = 350)
Endoleak No endoleak Endoleak No endoleak 
(n = 152) (n = 246) P value (n = 175) (n = 175) P value
AAA diameter (cm) 5.6 ± 1.0 5.5 ± 0.9 ns 5.6 ± 1.0 5.6 ± 0.9 ns
Neck diameter (cm) 2.2 ± 0.3 2.2 ± 0.2 ns 2.2 ± 0.3 2.2 ± 0.2 ns
Neck length (cm) 2.7 ± 1.4 2.8 ± 1.3 ns 2.8 ± 1.4 2.7 ± 1.2 ns
Calcification 77% 76% ns 78% 79% ns
Thrombus 81% 85% ns 84% 84% ns
AAA class 
A 26% 15% 23% 17%
B 47% 62% 50% 61%
C 16% 11% ns 15% 12% ns
D 6% 8% 7% 6%
E 5% 4% 4% 5%
AAA, Abdominal aortic aneurysm; ns, not significant.
discharge as defined by the core laboratory. Among
patients without endoleak as defined by the centers
at 12 months, mean aneurysm diameter decreased
more (–2.6 ± 5.1 mm) than in patients with
endoleak (–0.7 ± 4.0 mm) (P < .02) (Table V).
Patients with endoleak at 1 month as defined by
the centers had an increased risk of aneurysm
enlargement (12%) at 12 months, compared with
patients without endoleak (4%) (P < .05) (Table IV).
In addition, patients with Type I endoleaks at dis-
charge had an increased likelihood of aneurysm
enlargement (15%) compared with patients with no
Type I endoleak (5%, P > .01, Table VI). However,
only 22 patients (6%) had an increase in aneurysm
diameter of 5 mm or greater at any time (Table III),
and of these, only 15 (68%) had an endoleak at any
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time. Among 342 patients with no increase in
aneurysm diameter, 103 (30%) had an endoleak
reported at some time during the course of the
study. Thus, detection of an endoleak was poorly
correlated to increase in aneurysm size.
Stent graft migration 
Seven patients had radiologic evidence of stent
graft movement relative to the native aorta during the
course of the study. Three patients were successfully
treated with an additional endovascular procedure at
the time of appearance of a new endoleak and are
described among the additional procedures for
endoleak. Three patients have never had an endoleak,
and one had an endoleak at discharge and has a con-
tinuing endoleak with no change in aneurysm size.
Fig 4. Kaplan-Meier secondary outcome estimates (no death, no aneurysm rupture, and no conver-
sion to open surgical repair) for patients with and those without endoleaks at (A) hospital discharge.
A
Stent graft migration at any time during the course of
the study was identified in 3% of patients with
endoleaks at discharge and in 2% of patients with no
endoleak before hospital discharge. There was no dif-
ference between patients with endoleak and without
endoleak as defined by the centers or core laboratory.
There was no difference in stent graft migration rate
between patients with and without endoleak at 1
month. 
Primary outcome success
Primary outcome success was defined as no death,
no aneurysm rupture, no conversion to open surgical
repair, and no additional procedure for endoleak or
nonpatency of the stent graft. There was no difference
in Kaplan-Meier primary outcome estimates between
patients with and without endoleak before hospital
discharge as defined by the centers (Fig 3, A). There
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were no differences when these results were adjusted
for baseline group differences by the Cox proportion-
al model or if the analysis was carried out using the
core laboratory definition of endoleak. Primary out-
come was decreased (P < .001) in patients with
endoleak at 1 month compared with patients without
endoleak (Fig 3, B) because of the increase in addi-
tional procedures for endoleak and nonpatency.
Secondary outcome success
Secondary outcome success was defined as no
death, no aneurysm rupture, and no conversion to
open surgical repair. There was no difference in sec-
ondary outcome between patients with and without
endoleak before hospital discharge (Fig 4, A) and no
difference in secondary outcome between patients
with and without endoleak at one month (Fig 4, B).
There were no differences when these results were
Fig 4 Cont’d. Secondary outcome measure at (B) 1 month.
B
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adjusted for baseline group differences by the Cox
proportional model or if the analysis was carried out
using the core laboratory definition of endoleak.
Outcome by endoleak type
Outcome by endoleak type as determined by the
core laboratory is presented in Table VI. There were
no differences in death from any cause or aneurysm
rupture rate between patients with Type I or Type II
endoleaks and those with no endoleaks. Patients with
Type I endoleaks were more likely to undergo surgi-
cal conversion and experience aneurysm enlargement
compared with patients with no Type I endoleak (P
< .05). Patients with Type II endoleak were less like-
ly to experience a new endoleak compared with
patients without Type II endoleaks (P < .05). There
were no significant differences in primary or sec-
ondary outcome success in patients with Type I or
Type II endoleaks and those with no endoleaks.
DISCUSSION
Endovascular aneurysm repair has been shown to
have significant short-term benefits compared with
open surgical repair with reduced blood loss, reduced
hospital stay, reduced morbidity, and earlier return to
function.4,14,20-22 However, the long-term effective-
ness of endovascular repair in preventing aneurysm
rupture and death is unknown. Endoleaks have been
identified in 15% to 52% of patients after endovascu-
lar repair1,4,5,11,14 and have been related to aneurysm
rupture,10,13,15,23 but rupture has also been observed
in patients who have not had endoleaks after
endovascular repair.18,19 Although endoleak has been
called “the major complication of endovascular
aneurysm repair,”10,11,24,25 there is little evidence
that endoleak in and of itself represents an adverse
event of the procedure. Rather, endoleak is an indi-
cator of continued blood flow in the aneurysm sac
after endovascular repair. Presumably, the blood flow
in the aneurysm sac is less than it was before the stent
graft was placed in the aneurysm. How this alters the
natural history of the aneurysm is still undefined.
Thus, the significance of endoleaks and the determi-
nants of long-term outcome are unknown. 
Because the primary objective of aortic aneurysm
repair is to prevent aneurysm rupture and death
from rupture, we considered a successful primary
outcome after endovascular aneurysm repair to be
rupture-free survival with a patent stent graft, no
conversion to open surgical repair, and no need for
an additional endovascular procedure. A successful
primary outcome after stent graft repair by Kaplan-
Meier analysis was achieved in 92% of patients at 12
months and 88% of patients at 18 months in this
study. There was no significant difference in primary
outcome between patients with and those without
endoleak at the time of hospital discharge. This was
true whether the center or core laboratory determi-
nation of endoleak was used for the analysis. 
Rupture-free survival with a patent graft and no
conversion to open surgical repair were achieved
with the use of additional procedures to treat
endoleak or nonpatency of the graft in 6% of
patients. This resulted in a secondary outcome suc-
cess of 96% at 12 months and 94% at 18 months.
There was no difference in secondary outcome
between patients with and those without endoleak at
the time of hospital discharge. This was true whether
the center or core laboratory determination was
used for the analysis. Thus, endoleak at hospital dis-
charge is not a predictor of primary or secondary
outcome after endovascular aneurysm repair, nor is
endoleak at discharge a predictor of aneurysm
enlargement, stent graft patency, stent graft migra-
tion, or the appearance of new endoleaks. 
Patients with endoleak at 1 month, however, had
Table IV. Outcome after endovascular aneurysm repair
Predischarge CT 1 mo*
Endoleak No endoleak Endoleak No endoleak 
(n = 152) (n = 246) P value (n = 51) (n = 328) P value
Death 5% 5% ns 6% 3% ns
Aneurysm rupture 0.7% 0.0% ns 0% 0.3% ns
Surgical conversion 1% 0% ns 2% 0.3% ns
Additional procedure 8% 5% ns 16% 4% .01
Aneurysm enlargement 8% 4% ns 12% 4% .05
New endoleak 12% 7% ns 2% 10% ns
Migration 3% 2% ns 4% 2% ns
*Center data: duplex scan, 67%; CT, 33%.
ns, Not significant.
a reduced primary outcome success rate. In patients
with no endoleak at 1 month, primary success was
95% at 12 months and 92% at 18 months, whereas
patients with endoleak had a primary success rate of
86% at 12 months and 77% at 18 months (P < .001).
This difference was due entirely to the additional
endovascular procedures performed in the patients
with endoleak. The decision to treat endoleaks was
investigator determined and subject to investigator
bias as to the significance of the endoleak. Among
the nine patients with endoleak at discharge who
underwent additional endovascular treatment for
the endoleak, six continued with endoleaks after the
additional treatment. However, the six patients with
no endoleak at discharge who had new onset
endoleaks during the follow-up period were all suc-
cessfully treated with endovascular techniques to
eliminate the endoleak. There was no difference in
the secondary success rate at 18 months between
patients with endoleak at 1 month (91%) and those
without endoleak at 1 month (96%).
There is wide variability in the reported rate of
endoleak and lack of uniformity in classification and
quantification of endoleak.11,26,27,28 The endoleak
rate reported in this study is higher than the
endoleak rate reported in the first 150 patients treat-
ed with the AneuRx stent graft.4 This may be due to
the fact that the earlier report included the Phase I
feasibility study, which did not have the same focus
on postoperative imaging with independent core
laboratory review. Patient selection was more
restricted in Phase I and included only four study
sites, whereas this report of Phase II study patients
included 13 investigational sites. Endoleaks in this
study were evaluated by each clinical center as well
as by an independent, central core laboratory.
Endoleak classification was determined by the core
laboratory to ensure that consistency and criteria for
Type I and Type II endoleaks were maintained the
same throughout the study. Several refinements of
endoleak classification have been proposed since this
study was begun,24,26,28 but the reliability and accu-
racy of precisely defining the endoleak source have
not been defined. In this study, the source of
endoleak could not be determined in 29% of CT
scans. Perhaps more precise imaging techniques will
reduce the number of “undetermined” endoleaks in
the future. Although attachment site endoleaks are
meaningful and usually prompt additional treat-
ment, 89% of predischarge Type I endoleaks in this
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Fig 5. CT scan at 6 months of patient with aneurysm rupture at 14 months (same patient as in Fig 2)
demonstrating short, angulated neck with eccentric fixation of proximal stent graft. A, Infrarenal aor-
tic segment with tortuosity apparent at level of left renal artery. B, Eccentric fixation of proximal por-
tion of stent graft in tortuous infrarenal segment. C, Body of stent graft within aneurysm with no
endoleak. D, Bifurcation portion of stent graft with no endoleak.
study were not treated. Although no significant rela-
tionship between endoleak type and outcome was
identified in this study, the follow-up period is rela-
tively short. Longer-term follow-up may well identi-
fy certain endoleak types as meaningful predictors of
outcome. 
The endoleak rate reported by the study centers
was significantly lower than the endoleak rate
reported by the core laboratory according to the
evaluation of the same contrast-infused CT scans.
There are several possible explanations including a
potential bias to underread endoleaks by the centers
and a potential bias to overread endoleaks by the
core laboratory. In addition, the data set for evalua-
tion was not identical. The study sites had the advan-
tage of real-time access to the complete data set of
spiral CT images with both precontrast and post-
contrast infusion images as well as delayed images.
The center radiologist could order additional images
and adjust contrast technique as necessary to make a
determination. Hard copy CT film images may be
printed at variable intervals, such as every fourth
image, and the core laboratory had access to only
those films that it received. Noncontrast CT images
help differentiate calcium in the mural thrombus or
aneurysm wall from contrast in the aneurysm sac.
On occasion only the contrast CT images, but not
the noncontrast images, were sent to the core labo-
ratory. Thus, the higher reading of endoleak in the
core laboratory may be due, in part, to interpreta-
tion of calcium as endoleak. This highlights the dif-
ficulty in classification and quantification of
endoleaks with precision. Nonetheless, regardless of
the difference in overall endoleak rate, there was no
difference in evaluation of clinically significant fea-
tures such as the appearance of a new endoleak,
change in aneurysm size, or evidence of stent graft
migration between the centers and the core labora-
tory. Most important, there was no difference in the
analysis of clinical outcome that was based on
whether the center or core laboratory assessment of
endoleak was used.
Changes in aneurysm size have been related to
the presence or absence of endoleak. An increase in
aneurysm size has been related to the presence of
endoleak, whereas absence of an endoleak has been
associated with a decrease in aneurysm size.16,27,29,30
In this study the presence of endoleak before hospi-
tal discharge was not associated with an increased
likelihood of increase in aneurysm size, nor was the
absence of endoleak associated with an increased like-
lihood of decrease in aneurysm size. Most aneurysms
did not change and remained within 0.5 cm of their
original diameter at 12 months. However, all
endoleaks are not the same, and certain endoleak
types, such as those related to device attachment or
fixation (Type I), have greater significance. In this
study, patients with Type I endoleaks had a threefold
increased likelihood of experiencing aneurysm
enlargement at 1 year than those without Type I
endoleaks. Endoleaks that persisted longer than 1
month also had an increased likelihood of aneurysm
enlargement at 1 year. However, only 6% of patients
had any aneurysm enlargement during the follow-up
period, and 42% of these patients had no endoleak of
any type at any time during the study. Thus, endoleak
was not a reliable indicator of a propensity for
aneurysm enlargement. 
The low predictive value of the postprocedure
contrast CT suggests that CT scans may not always
be essential before hospital discharge. Duplex ultra-
sound scanning can potentially be used before dis-
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Table V. Aneurysm diameter changes over time compared with predischarge CT
Centers Core laboratory
Endoleak No endoleak P value Endoleak No endoleak P value
At 6 mo
Increase > 5 mm 4% 2% ns 4% 2% ns
Decrease > 5 mm 7% 10% ns 8% 9% ns
No change 89% 88% ns 88% 89% ns
Diameter change (mm) –0.5 ± 2.0 –1.3 ± 4.0 ns –0.7 ± 3.3 –1.2 ± 4.0 ns
At 12 mo
Increase > 5 mm 8%* 2% ns 7% 1% ns
Decrease > 5 mm 14%* 25% ns 17% 24% ns
No change 78%* 73% ns 76% 75% ns
Diameter change (mm) –0.7 ± 4.0 –2.6 ± 5.1 .02 –1.7 ± 5.3 –2.1 ± 4.6 ns
*Overall significance P = .03.
ns, Not significant.
charge to image the aortic aneurysm and stent graft,
to record aneurysm size, and to identify endoleaks.30
Timing of the postprocedure contrast CT at 1
month after the procedure offers the advantage of
avoiding an additional contrast load to the patient
within a short time of the endovascular procedure,
particularly if there is borderline or compromised
renal function. Second, at the 1-month time period,
many early endoleaks will be closed. Endoleak status
at 1 month appears to be more meaningful than
endoleak status at hospital discharge, and elimina-
tion of the predischarge CT would reduce proce-
dure-related hospital costs.
A number of investigators have focused on
endoleaks, identifying them as the primary failure
mode of endovascular repair, and have closely relat-
ed them to risk of aneurysm rupture.10,11,24
However, many reports include a variety of stent
grafts with differing reasons for failure, including
endovascular devices in the early stages of develop-
ment and those that are no longer manufac-
tured.10,11 Some of the ruptures and failures have
been related to fabric or device structural fail-
ure,29,32-35 which may not occur in improved stent
graft designs. Although failures have been linked to
endoleaks, the endoleak may simply be the method
by which the failure was identified and demonstrat-
ed, rather than providing evidence that flow in the
aneurysm sac is the prerequisite cause of rupture. 
Untreated aneurysms all have large endoleaks,
and not all aneurysms rupture. The risk of rupture of
untreated aneurysms is related to aneurysm size.
Aneurysm enlargement and rupture may be deter-
mined by factors other than whether there is blood
flow in the aneurysm sac.36 The annual expansion
rate of aneurysms ranges from 6.5% to 20.6% of
diameter per year.37 If one assumes an average
increase in diameter of 10% per year and the average
aneurysm diameter in this series was 56 mm, then
the expected increase in aneurysm diameter at 1 year
would have been 5.6 mm. We observed that
aneurysm size did not change or decreased in 92% of
patients with endoleaks, suggesting that despite con-
tinued blood flow in the aneurysm sac the natural
tendency for aneurysms to enlarge was altered in
most patients. Similarly, 98% of patients without
endoleak had no change or a decrease in aneurysm
diameter. However, 2% of patients without endoleak
had an increase in diameter of more than 5 mm,
indicating that diameter changes are possible with-
out evidence of endoleak.
Consideration of endoleak as a primary end
point of treatment rather than prevention of
aneurysm enlargement and rupture may lead to sig-
nificant adverse patient outcome. A focus on
endoleak and the elimination of endoleak as an end
point of treatment may expose the patient to an
increased risk of aneurysm rupture.34,38 Clinical
treatment of aneurysms in the past has been guided
by aneurysm size and changes in diameter or symp-
toms, and there is no evidence that there should be
a change in favor of endoleaks.
Furthermore, absence of endoleak is no assur-
ance that the patient is free of the risk of rupture.
This is illustrated by the patient in this series who
had aneurysm rupture at 14 months. This patient
had an endoleak at hospital discharge related to the
modular iliac junction site. This was sealed at 1
month and remained sealed for 1 year with no
endoleak. The aneurysm ruptured at 14 months
because of dislodgment of proximal fixation in a
short, angulated infrarenal neck (Fig 5), a site
remote from the source of the earlier endoleak. 
One additional patient treated with an AneuRx
stent graft has experienced aneurysm rupture during
this follow-up period. This second patient was
among the 40 patients treated in Phase I of the
AneuRx Clinical Trial.4 This patient was aged 70
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Table VI. Outcome by endoleak type
Outcome Type I (N = 54) Type II (N = 70) No endoleak (N = 175)
Death (any cause) 2 4% 3 4% 7 4%
Aneurysm rupture 1 2% 0 0% 0 0%
Surgical conversion 2* 4% 0 0% 0 0%
Additional procedure 4 7% 1 1% 7 4%
Aneurysm enlargement 8* 15% 5 7% 6 3%
New endoleak 3/42 7% 0† 0% 10 6%
Migration 1 2% 2 3% 4 2%
Primary success 46 85% 66 94% 161 92%
Secondary success 50 93% 67 96% 168 96%
*P < .05 compared with no Type I endoleak.
†P < .05 compared with no Type II endoleak.
years and had a 5.5-cm aneurysm at the time of
endovascular repair. The aneurysm was successfully
excluded with no endoleak at hospital discharge and
no endoleak at 1 month, 6 months, and 12 months.
Aneurysm diameter was unchanged and measured
5.5 cm at 6 months and 12 months. At 23 months,
the patient had back pain and underwent successful
open repair of a ruptured aortic aneurysm. Review
of morphologic features of this aneurysm also
revealed a short angulated neck, raising the possibil-
ity that this anatomic feature may identify patients
with less secure proximal fixation who may need
closer follow-up. It highlights the fact that
aneurysms may rupture after endovascular repair
with no evidence of endoleak18,19 and that other
measures such as aneurysm size changes and stent
graft fixation configuration may be more important
than endoleak status in identifying patients at risk for
future adverse events. 
Considering both Phase I and Phase II data, it
appears that the aneurysm rupture rate after AneuRx
stent graft repair of 5.6-cm abdominal aneurysms is
0.5% up to 2 years. This can be compared with an
expected rupture rate of approximately 11% per year
for 5- to 6-cm aneurysms37 that are untreated. Thus,
endovascular repair markedly reduces, but does not
entirely eliminate, the risk of aneurysm rupture.
Endoleak, however, does not appear to be a reliable
predictor of those patients who may be at future risk
of rupture. Thus, all patients, regardless of endoleak
status, should be followed up closely.
The 18-month cumulative survival rate of 94% in
this study compares favorably with an 86% 2-year
cumulative survival rate reported by the French
Vanguard Trial5 and an 88% 2-year survival rate
reported by May et al.20 It also compares favorably
with long-term survival after open surgical
repair.39,40 The 18-month survival rate free of rein-
tervention in this study was 88% compared with a
67% 2-year cumulative survival free of intervention
reported by the multicenter French Vanguard Trial.5
In conclusion, endoleak is commonly seen after
endovascular repair, but is a poor predictor of the
most important clinical outcome measures such as
death or aneurysm rupture. Thus, the usefulness of
endoleak as a primary indicator of success or failure of
endovascular aneurysm repair is uncertain. A primary
focus on endoleak and its treatment or prevention
may divert attention from potentially more important
considerations such as adequate stent graft fixation
and changes in aneurysm size. It is well known that
aneurysm size and change in size are closely related to
the risk of rupture. Patients with known, untreated
aortic aneurysms are followed up with periodic
aneurysm imaging focused primarily on determining
aneurysm size. The same strategy with modification
to evaluate endovascular device morphology and fixa-
tion might be used in patients who have undergone
endovascular aneurysm repair. Physicians with knowl-
edge of the natural history of aneurysms and an
understanding of the spectrum of endovascular and
open surgical treatment strategies should be involved
with the ongoing care, long-term follow-up, and
management of patients with aortic aneurysms.
We thank the AneuRx Clinical Investigators and the
Medtronic AneuRx Clinical support team, Tami Crabtree
for statistical evaluation, and Rita Wedell for preparation
of the manuscript.
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ADDENDUM
Since completion of this analysis and presentation
of these data at the Western Vascular Society Meeting
on September 22, 1999, there have been five addi-
tional patients with aneurysm ruptures after AneuRx
stent graft repair. Thus, there have been a total of
seven aneurysm ruptures (0.7%) following successful
implantation among 1046 patients in Phases I, II, and
III of the AneuRx Clinical Trial that began in June
1996. Three of these patients were described in the
March 2000 issue of the Journal of Vascular Surgery
(Politz JK, Newman VS, Stewart MT. Late abdominal
JOURNAL OF VASCULAR SURGERY
Volume 32, Number 1 Zarins et al 107
aortic aneurysm rupture after AneuRx repair: a report
of three cases. J Vasc Surg 2000;31:599-606). The
full report of these seven patients appears in the May
2000 issue of the Journal of Vascular Surgery (Zarins
CK, White RA, Fogarty TJ. Aneurysm rupture after
endovascular repair using the AneuRx stent graft. J
Vasc Surg 2000;31:960-70).
Of note is the fact that among these seven
patients, three had endoleak at hospital discharge, and
four had no endoleak. At 1 month two patients had
endoleak, and five had no endoleak. The two patients
with endoleak refused recommended endovascular or
open surgical treatment and ruptured 15 and 24
months later. The five patients without endoleak con-
tinued to be free of endoleak at the time of the last
examination before rupture. Retrospective review of
abdominal radiographs and CT scans identified inse-
cure stent graft attachment or fixation in each of the
five patients. Each could potentially have been cor-
rected with endoluminal extender cuffs.
This experience confirms the observation in this
study that the presence of an endoleak is not a reli-
able predictor of subsequent outcome events.
Furthermore, the absence of an endoleak does not
ensure that the patient is free of the risk of aneurysm
rupture. Although the risk of aneurysm rupture is
small, all patients with endovascular aneurysm repair
regardless of endoleak status should be followed up
by periodic imaging. If insecure stent graft fixation
or attachment is suspected or if there is evidence of
aneurysm enlargement or if there is new onset
endoleak, further treatment should be considered.
DISCUSSION
Dr Christopher Zarins. Thank you, Dr Taylor, for
your discussion.
Regarding the patient who ruptured, we analyzed
that patient both ways. The patient had an endoleak at
the time of discharge, and we analyzed that patient in the
endoleak group. The patient did not have an endoleak at
the time of the 1-month study, and thus we analyzed the
patient in that analysis in the no-endoleak group.
Whichever way you analyzed it, it made no difference.
The outcome was the same. Whether or not you had an
endoleak was not a predictor of what was going to 
happen in the future.
Regarding the type of endoleak, overall we had 30%
Type I endoleaks, 40% Type II endoleaks, and 30% unde-
termined. On CT scan it may be hard to be precise in the
definition of what is a Type I and what is a Type II
endoleak. To a large extent that is a subjective interpreta-
tion. For this analysis we relied on the core laboratory
interpretation and classification. Certainly on an individual
patient basis when you see an attachment site defect, that
is a significant finding that merits more attention.
Regarding the question of what we really do, how we
evaluate patients, and what needs to be looked at to follow
patients, I think that the criterion that we really can follow
is aneurysm size. After all, that is the criterion that we
always have followed as we have looked and thought
about aneurysms. We have always taken the risk benefit
analysis of aneurysm size versus patient comorbidities and
considered  the risks of open repair versus no treatment.
It is a complex algorithm that we as vascular surgeons
have done all of our professional lives, and I think 
we should continue to use that same algorithm and
approach.
The problem that I see is a focus on endoleak as a pri-
mary outcome measure. Some people think that we are
here to fix endoleaks, and, in fact, that approach can be
dangerous. Patients have ruptured their aneurysms
because of that approach. There are published reports in
the literature of repeated efforts to seal endoleaks despite
increasing aneurysm size with ultimate rupture. The prob-
lem was the focus on the endoleak rather than the pro-
gressive enlargement.
So how do we evaluate the success of endovascular
repair? We usually compare endovascular grafts to open
surgical repair. Perhaps we should also compare endo-
grafts to nonoperative treatment where we consider the
natural history of aneurysms. The annual risk of rupture
of untreated aneurysms of the size treated in this study is
perhaps 10% per year. After we place an endograft, the risk
is reduced to less than half of 1%.
From our data there is no evidence that the presence or
absence of an endoleak will predict those at continuing risk
of rupture. Subsequent outcome is primarily dependent on
patient comorbidities according to our data analysis.
